Illumina, Inc. (NASDAQ:ILMN) stock rose 1.89% (As on November 4, 1:51:51 AM UTC-4, Source: Google Finance) after the company posted better than expected results for the third quarter of FY 22. Capital expenditures for free cash flow purposes were $67 million during the third quarter of 2022. Cash flow used in operations was $(52) million, which included a one-time payment related to the litigation settlement with BGI, compared to $(272) million in the prior year period, which included transaction expenses related to the GRAIL acquisition on August 18, 2021. Free cash flow (cash flow used in operations less capital expenditures) was $(119) million for the quarter, compared to $(324) million in the prior year. At the close of the quarter, the company held $1,041 million in cash, cash equivalents and short-term investments, compared to $1,339 million as of January 2, 2022.

ILMN in the third quarter of FY 22 has reported the adjusted earnings per share of 34 cents, beating the analysts’ estimates for the adjusted earnings per share of 29 cents. The company had reported the adjusted revenue growth of 1 percent to $1.12 billion in the third quarter of FY 22, beating the analysts’ estimates for revenue of $1.1 billion.

On the other hand, the company has announced multiple breakthrough sequencing innovations at the inaugural Illumina Genomics Forum, including NovaSeqX Series (NovaSeq X and NovaSeq X Plus), available in Q1 2023, enabling the highest levels of accuracy at immense scale, with the power to sequence more than 20,000 genomes per year. NovaSeq 6000Dx, available now as the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer. Illumina Complete Long-Reads, available in 2023, delivering a complete and accurate representation of the genome at the single molecule on both existing and new sequencing platforms. XLEAP-SBS Chemistry on the NextSeq 1000/2000 available in 2024. The company has partnered with GenoScreen to expand global access to genomic testing for multi-drug resistant tuberculosis (TB) by combining Illumina sequencing products and the GenoScreen Deeplex® Myc-TB assay, a targeted next-generation sequencing (NGS) based test for rapid and extensive detection of anti-TB drug resistance. The company has deepened strategic collaboration with AstraZeneca to accelerate drug target discovery based on human omics insights by combining strengths in artificial intelligence based genome interpretation and genomic analysis along with industry expertise.